Möchten Sie immer auf dem neuesten Stand bleiben?

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric...

Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its...

Dublin, March 04, 2026 (GLOBE NEWSWIRE) -- The "Personalized Medicine Biomarkers Market Outlook 2026-2034: Market Share, and Growth Analysis" has been added to ResearchAndMarkets.com's offering. ...

ICPO und UroTeragLATAM gehen strategische Partnerschaft ein, um Theranostik für urologische Krebserkrankungen in Lateinamerika zu fördern

ICPO und UroTeragLATAM gehen strategische Partnerschaft ein, um Theranostik für urologische Krebserkrankungen in Lateinamerika zu fördern

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapeutics in Cancer Treatment: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for radioligand...

Dublin, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The "Precision Medicine in Oncology Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a...

Patent for composition of matter and methods of use of high-radiopure diagnostic ⁶¹Cu-NU101 and combination use with therapeutic pair ⁶⁷Cu-NU101